Patents by Inventor Olivier Delattre

Olivier Delattre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220401539
    Abstract: The present disclosure relates to a tumor specific neoantigenic peptide, wherein said peptide (i) is encoded by a part of an (ORF) sequence from an unannotated transcript which transcription is positively regulated by an aberrant fusion protein, and (ii) is expressed at a higher level or frequency in a sample from said tumor compared to normal tissue sample. The present disclosure also relates to vaccine or immunogenic composition, antibodies and immune cells derived thereof and their use in therapy of cancer.
    Type: Application
    Filed: October 22, 2020
    Publication date: December 22, 2022
    Applicants: Institut Curie, Institut National de la Santé et de la Recherche Médicale
    Inventors: Olivier Delattre, Olivier Saulnier, Joshua Waterfall, Céline Collin, Julien Vibert, Maud Gautier
  • Patent number: 5968734
    Abstract: Translocations of chromosome 22 are associated with various cancers. Hybrid DNA sequences, having a portion of the Ews gene of chromosome 22 and a portion of either the Hum-Fli-1 gene of chromosome 11, the Erg gene of chromosome 21, or the Atf-1 gene of chromosome 12, are disclosed. Proteins encoded by these hybrid DNAs are disclosed. Diagnosis of specific cancers based on detection of the translocations is disclosed.
    Type: Grant
    Filed: January 18, 1995
    Date of Patent: October 19, 1999
    Assignee: (CNRS Centre National de la Recherche Scientifique
    Inventors: Alain Aurias, Olivier Delattre, Chantal Desmaze, Thomas Melot, Martine Peter, Beatrice Ploougastel, Gilles Thomas, Jessica Zucman